{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1382262944558569733.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Kiyean Nam"}],"foaf:familyName":[{"@value":"Nam"}],"foaf:givenName":[{"@value":"Kiyean"}]}],"career":[{"institution":{"notation":[{"@value":"Qurient Incorporated, 16 Daewnagpangyo-ro,\r712 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Korea"}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1362262944558569728","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1021/jm5003606"},{"@type":"URI","@value":"https://pubs.acs.org/doi/pdf/10.1021/jm5003606"}],"notation":[{"@value":"Lead Optimization of a Novel Series of Imidazo[1,2-<i>a</i>]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1021/jm5003606_rLVPams13bCK2UERw82F0bQUv5"}]}